Kingstronbio (Changshu) Co., Ltd. announced that it has signed a capital increase agreement for private placement of CNY 125 million on January 20, 2018. The transaction will included participation from new investors Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) for CNY 100 million and 10.81% stake out of which CNY 8.6534 million will go into registered capital, Jiangsu Jiequan Xingong Bangsheng Venture Capital Fund Partnership Enterprise for CNY 14.5 million and 1.57% stake out of which CNY 1.257 million will go to registered capital, Yao Haosheng for CNY 10 milion for 1.08% stake out of which CNY 0.8653 million will go to registered capital, and existing investor Nanjing Bangsheng Juyuan Investment Management Partnership Enterprise for CNY 0.5 million out of which CNY 0.2826 million will go to registered capital of the company. Nanjing Bangsheng Juyuan Investment Management Partnership Enterprise will retain its stake of 0.35% in the company. The transaction does not need the approval of the company’s directorate and shareholders.